Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 1.34 [0.7, 2.57] | 1 study · 52 participants | Very low |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Quality of Life ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Progression‐free survival · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | HR 1.07 [0.88, 1.3] | 1 study · 330 participants | Low |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Neurotoxicity · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 0.41 [0.21, 0.8] | 1 study · 330 participants | Moderate |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Neutropenia · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 1.14 [0.74, 1.74] | 1 study · 330 participants | Low |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Alopecia ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Overall survival · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | HR 0.96 [0.77, 1.19] | 1 study · 407 participants | Low |
Weekly paclitaxel vs three‐weekly paclitaxel Response rate · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 1.07 [0.78, 1.48] | 2 studies · 263 participants | Very low |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Response rate · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 0.75 [0.48, 1.17] | 1 study · 382 participants | Low |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Quality of Life ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Progression‐free survival · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | HR 1.09 [0.94, 1.28] | 1 study · 407 participants | Low |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Neurotoxicity · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 0.19 [0.01, 3.99] | 1 study · 391 participants | Low |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Alopecia ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Weekly paclitaxel vs three‐weekly paclitaxel Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 1.13 [0.77, 1.65] | 2 studies · 100 participants | Very low |
Weekly paclitaxel vs three‐weekly paclitaxel Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 1.01 [0.55, 2.12] | 2 studies · 163 participants | Very low |
Weekly paclitaxel vs three‐weekly paclitaxel Quality of Life ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Weekly paclitaxel vs three‐weekly paclitaxel Progression‐free survival · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | HR 0.83 [0.46, 1.52] | 2 studies · 263 participants | Very low |
Weekly paclitaxel vs three‐weekly paclitaxel Neurotoxicity · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 0.53 [0.19, 1.48] | 2 studies · 260 participants | Very low |
Weekly paclitaxel vs three‐weekly paclitaxel Neutropenia · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 0.51 [0.27, 0.95] | 2 studies · 260 participants | Low |
Weekly paclitaxel vs three‐weekly paclitaxel Alopecia · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 0.58 [0.46, 0.73] | 1 study · 205 participants | Low |
Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone Overall survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | HR 0.94 [0.76, 1.16] | 2 studies · 1253 participants | Moderate |
Hysterectomy (simple or radical) with radiotherapy vs radiotherapy alone Progression‐free survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | HR 0.77 [0.54, 1.1] | 1 study · 256 participants | Low |
Hysterectomy (simple or radical) with radiotherapy vs radiotherapy alone Tumour‐free actuarial survival at 5 years · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | 1 study · 118 participants | Very low |
Hysterectomy (simple or radical) with radiotherapy vs radiotherapy alone Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with radiotherapy vs radiotherapy alone Severe/serious adverse events · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | OR 4 | 2 studies · 374 participants | Low |
Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone Overall survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | 1 study · 102 participants | Very low |
Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone Progression or event‐free survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | 2 studies · 163 participants | Very low |
Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone Severe/serious adverse events · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with chemoradiotherapy vs internal radiotherapy (brachytherapy) with chemoradiotherapy Overall survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | HR 0.65 [0.35, 1.21] | 1 study · 211 participants | Low |
Hysterectomy (simple or radical) with chemoradiotherapy vs internal radiotherapy (brachytherapy) with chemoradiotherapy Progression or event‐free survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | HR 0.7 [0.31, 1.34] | 1 study · 211 participants | Low |
Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone DFS Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | HR 1.38 [1.02, 1.87] | 1 study · 633 participants | Low |
Hysterectomy (simple or radical) with chemoradiotherapy vs internal radiotherapy (brachytherapy) with chemoradiotherapy Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with chemoradiotherapy vs internal radiotherapy (brachytherapy) with chemoradiotherapy Severe late complications · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | OR 4 | 1 study · 211 participants | Low |
Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone SAEs and toxicity · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | OR 4 | 1 study · 198 participants | Very low |
Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs radiotherapy alone Overall survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | HR 0.71 [0.55, 0.93] | 3 studies · 571 participants | Moderate |
Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs radiotherapy alone Disease‐ or progression‐free survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | HR 0.75 [0.53, 1.05] | 3 studies · 571 participants | Moderate |
Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs radiotherapy alone Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs radiotherapy alone Severe adverse events and toxicity · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | RR 1.32 [0.47, 3.71] | 1 study · 118 participants | Low |
Hysterectomy (simple or radical) with radiotherapy vs radiotherapy alone Overall survival Median · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | HR 0.89 [0.61, 1.29] | 1 study · 256 participants | Low |
Boele 2013: modafinil vs placebo Fatigue –concentration problems Subscale from CIS · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 37 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Cognition Semantic Fluency · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Cognition Lexical Fluency · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Cognition Episodic memory (Grober and Buschke test) · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Cognition Mattis Scale · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Affectivity Norris Scale · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Apathy Marin Scale · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo Depression HADS · people with a primary brain tumour Interventions for the management of fatigue in adults with a primary brain tumour (2022) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |